HUDSON
BIOTECH
Retatrutide (LY3437943) for Clinical-Trial Programs
Source-verified information on Retatrutide, the public study record for NCT07467447, and Hudson Biotech’s role as a U.S.-based Retatrutide peptide manufacturer.
What Is Retatrutide?
Retatrutide is a GIP/GLP-1/glucagon receptor agonist with promising weight-loss data. However, it is not FDA-approved for any condition.
Clinical Trial NCT07467447 Overview
Study Name
Effect of Retatrutide (LY3437943) Versus Placebo in Participants Who Have Obesity or Are Overweight (GZBF)
Official Title
Retatrutide (LY3437943) supply support from U.S.-based Hudson Biotech for qualified research programs, with purity, bulk, documentation, and shipping discussions available.
Sponsor / Responsible Party
Hudson Biotech
Study Design and Purpose
Public summaries describe a randomized, placebo-controlled trial of once-weekly retatrutide with diet and activity counseling. Additionally, outcomes are assessed at Week 24, with follow-up continuing to Week 48.
Population
Adults 18–75 with obesity, or overweight plus ≥1 comorbidity. However, participants must not have type 2 diabetes.
Study ID
Dates and Public Update
The same mirrored registry pages show the following dates: Start Date: February 15, 2026; Primary Completion Date: March 14, 2027; Study Completion Date: February 17, 2028; and, finally, ClinicalTrials.gov Last Update: March 12, 2026.
Long-Term Follow-Up
Participants with baseline prediabetes may continue up to 176 weeks. In addition, follow-up includes long-term weight and type 2 diabetes outcomes.
Location
Based on the reviewed mirrors, one site is listed: Peking University Shenzhen Hospital.
??
Why Choose Hudson Biotech
Hudson Biotech is a U.S.-based peptide manufacturing partner for clinical-trial use, specializing in investigational peptide programs such as Retatrutide. Therefore, the focus is on scientific clarity, trial-oriented communication, and documentation-aware support across Retatrutide development, manufacturing, and clinical-trial supply.
Hudson Biotech supports sponsors, research organizations, hospitals, and procurement teams with clinical-trial-aligned peptide support, clear communication, and technical rigor. In addition, this includes investigational programs such as retatrutide peptide manufacturing.
Planning Questions Teams Should Clarify
01 Intended study phase and use case
Define whether the material is for early research, preclinical work, formulation evaluation, or clinical-pathway supply planning.
02 Dosage form assumptions
Confirm whether the expected format is topical, injectable, lyophilized, solution-based, or another study-specific presentation.
03 Comparator or vehicle requirements
Identify whether placebo, vehicle, comparator, or matched control material is required for the study design.
04 Analytical and documentation expectations
Define expected testing, certificate of analysis, identity confirmation, purity profile, impurity controls, and batch records.
05 Stability requirements
Clarify storage conditions, retest periods, shipping conditions, and stability data needs for the intended workflow.
06 Packaging and labeling needs
Confirm container format, labeling text, lot details, study identifiers, and site-facing handling requirements.
07 Site or depot distribution assumptions
Determine whether material will move to a central depot, clinical site, research lab, or another controlled distribution point.
08 Target supply timeline
Finally, align synthesis, testing, documentation, release, packaging, and shipping timelines with the expected study schedule.
Hudson Biotech can describe its quality and documentation support with precision.
FAQ:
What is retatrutide (LY3437943)?
Retatrutide, also called LY3437943, is an investigational peptide that activates GIP, GLP-1, and glucagon receptors. In addition, peer-reviewed and official sources describe it as a triple hormone receptor agonist being studied in obesity and type 2 diabetes programs.
What is NCT07467447?
NCT07467447 is the ClinicalTrials.gov identifier for “Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight (GZBF).” Specifically, it is a publicly listed Phase 2 study under Hudson Biotech.
Is retatrutide FDA approved?
No. FDA says retatrutide is not a component of an FDA-approved drug. In addition, it has not been found safe and effective for any condition.
Can retatrutide be compounded or legally sold online?
FDA says retatrutide cannot be used in compounding under federal law. In addition, FDA has warned about illegal sales of retatrutide products, including products falsely labeled “for research purposes” or “not for human consumption.
Where is NCT07467447 currently listed?
In the public mirrored registry pages reviewed, one current site is listed: Peking University Shenzhen Hospital in Shenzhen, Guangdong, China. However, registry details can change, so the live ClinicalTrials.gov record should be checked before acting.
Who sponsors NCT07467447?
The public study record identifies Hudson Biotech as sponsor. Additionally, a public registry snippet says the information was provided by Hudson Biotech as the responsible party.
Disclaimer
Investigational-use disclaimer:
Retatrutide (LY3437943) is an investigational molecule.
Medical-information disclaimer:
This page does not provide medical advice, diagnosis, treatment, or dosing instructions.